IA Trial Radar | ||
|---|---|---|
O estudo clínico NCT07481526 para Doença renal crônica está em recrutamento. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui. | ||
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa
AstraZenecaA Prospecitve Multicenter, Observational Registry Study 3.000 Observacional
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT07481526 é um estudo observacional para Doença renal crônica. Seu status atual é: em recrutamento. O estudo começou em 27 de fevereiro de 2026 e pretende incluir 3.000 participantes. Coordenado por AstraZeneca e deve ser concluído em 30 de dezembro de 2028. Essas informações foram atualizadas no ClinicalTrials.gov em 19 de março de 2026.
Resumo
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Descrição detalhada
To ensure a nationally representative cohort, a total of approximately 3000 participants will be enrolled from around 80 sites strategically selected from various geographic regions in China. The sites will include a mix of top-tier tertiary hospitals, regional medical centers, and representative secondary hospitals to accurately reflect real-world clinical practice at different levels of care. All enrolled participa...Mostrar mais
Título oficial
A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
Condições médicas
Doença renal crônicaOutros IDs do estudo
- D4327R00004
Número NCT
Data de início (real)
2026-02-27
Última atualização postada
2026-03-19
Data de conclusão (estimada)
2028-12-30
Inscrição (estimada)
3.000
Tipo de estudo
Observacional
Status
Em recrutamento
Desfecho primário
Desfecho secundário
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively | To determine the prevalence of HP, HF, HTN, and HK among patients with CKD | baseline |
Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i) | To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK | To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients with HK | To describe HK outcomes of HK recurrence for all CKD patients with HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients with HK | To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK. | Week 0 to week 96 |
Clinical outcomes of CKD patients with HK | To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Proportion of patients achieving UACR \<700 mg/g with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Proportion of patients achieving UPCR \< 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK | To describe the clinical indicators of Proportion of patients achieving UPER \<1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK. | Week 0 to week 96 |
Clinical indicators for CKD patients with HP and HTN | To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN. | Week 0 to week 96 |
Clinical indicators for CKD patients with HP and HTN | To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN. | Week 0 to week 96 |
Clinical indicators for CKD patients with HP and HTN | To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN. | Week 0 to week 96 |
Clinical indicators for CKD patients with HF | To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF. | Week 0 to week 96 |
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of eGFR slope between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
The HCRU among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | To describe healthcare resource utilization (HCRU) among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicators eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of Composite outcome of eGFR decline ≥50% between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of Change in eGFR from baseline over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of change in UACR from baseline over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of change in UPCR from baseline over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of change in UPER from baseline over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of proportion of patients achieving UACR \<700 mg/g with ≥30% reduction over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of Proportion of patients achieving UPER \<1000 mg/24h with ≥30% reduction over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP and HTN | To compare the clinical indicators of Change in systolic BP from baseline over time between CKD patients with or without HP, HTN | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP and HTN | To compare the clinical indicators of change in diastolic BP from baseline over time between CKD patients with or without HP, HTN | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP and HTN | To compare the clinical indicators of proportion of patients achieving BP control target over time between CKD patients with or without HP, HTN | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HF | To compare the clinical indicators of Change of NT-proBNP from baseline over time between CKD patients with or without HF | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of proportion of patients achieving UACR \<700 mg/g with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of proportion of patients achieving UPCR \< 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of proportion of patients achieving UPER \<1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in systolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of change in diastolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups | To identify the factors associated with the clinical indicator of Proportion of patients achieving BP control target over time in patients with CKD overall, and in subgroups with HP,HTN | Week 0 to week 96 |
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF | To identify the factors associated with the clinical indicator of change of NT-proBNP from baseline over time in patients with CKD overall, and in subgroups with HF | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the composite outcome of eGFR decline ≥50% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the composite outcome of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the composite outcome of renal death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the composite outcome of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the renal outcomes of ≥50% eGFR decline from baseline in patients with CKD overall, and in subgroups with HP,HTN | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the renal outcomes of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the renal outcomes of RRT in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with the renal outcomes of CKD stage progression in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with renal-related death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with CV outcomes of MACE in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with CV outcomes of HF in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with CV outcomes of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with CV outcomes of all-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with CV outcomes of all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK | To identify the factors associated with HK outcomes of HK recurrence in patients with CKD overall, and in subgroups with HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK | To identify the factors associated with HK outcomes of severe HK requiring hospitalisation in patients with CKD overall, and in subgroups with HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK | To identify the factors associated with HK outcomes of severe HK requiring emergency-department visits in patients with CKD overall, and in subgroups with HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of composite outcome of ESRD between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of composite outcome of renal death between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of composite outcome of CV death between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of Renal outcomes of ≥50% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of Renal outcomes of ESRD between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of Renal outcomes of RRT between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of CKD stage progression between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of Renal-related death between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of CV outcomes of MACE between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of CV outcomes of hHF between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of All-cause death between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical outcomes of All-cause hospitalization between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HK | To compare the clinical outcomes of HK recurrence between CKD patients with or without HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HK | To compare the clinical outcomes of Severe HK requiring hospitalisation between CKD patients with or without HK | Week 0 to week 96 |
Clinical outcomes of CKD patients and CKD patients with HK | To compare the clinical outcomes of Severe HK requiring emergency-department visits between CKD patients with or without HK | Week 0 to week 96 |
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK | To compare the clinical indicators of proportion of patients achieving UPCR \< 1000 mg/g and ≥ 30% reduction from baseline over time between CKD patients with or without HP, HF, HTN, HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with All-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK | To identify the factors associated with all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK | Week 0 to week 96 |
Assistente de participação
Critérios de elegibilidade
Idades elegíveis
Criança, Adulto, Idoso
Sexos elegíveis
Todos
Male or female patients aged ≥18 years.
Willing and able to provide written informed consent to participate in the study.
Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
- eGFR <60 mL/min/1.73 m² for ≥3 months, OR
- Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months
- Having a life-threatening comorbidity with life expectancy < 2 years.
- Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
- Pregnant or breastfeeding women.
- Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
- Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
AstraZenecaContato central do estudo
Contato: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
1 Locais do estudo em 1 países
Zhongshan Hospital Affilicated with Fudan University, Shanghai, China
Em recrutamento